Navigation Links
Cantel Medical Reports 25% Increase in Net Income - EPS of $0.35 vs. $0.29 - for Quarter Ended October 31, 2011 on 30% Sales Increase

LITTLE FALLS, N.J., Dec. 8, 2011 /PRNewswire/ -- CANTEL MEDICAL CORP. (NYSE: CMN) reported a 25% increase in net income to $6,220,000, or $0.35 per diluted share, on a 30% increase in sales to a record $93,262,000 for the first quarter ended October 31, 2011. This compares with net income of $4,975,000, or $0.29 per diluted share, on sales of $71,993,000 for the first quarter ended October 31, 2010.

Andrew Krakauer, Cantel's President and CEO stated, "We are pleased to have delivered record sales and strong quarterly earnings. These positive results confirm the continued success of our three prong approach to growth which includes investing in new product development, sales and marketing programs and acquisitions. All of these strategies positively affected the results this quarter."

Krakauer added, "Our Endoscopy segment had an especially stellar performance this quarter as organic sales grew by 25%, excluding sales from our newly acquired Byrne Medical business. This growth was driven by increased shipments of our newest reprocessor, the DSD Edge™, as well as disinfectants and sterilants, parts and service.  Byrne Medical, which is in the process of being integrated into the Endoscopy segment, had core sales growth in excess of 30% and was accretive to earnings in the quarter. We also had excellent performance in our Water Purification and Filtration segment, where sales growth of 21% and effective integration of the Gambro water acquisition resulted in a 57% increase in operating income."

The Company also reported that its balance sheet at October 31, 2011 included current assets of $118,617,000, including cash of $19,646,000, a current ratio of 2.27:1, gross debt of $116,500,000 and stockholders' equity of $247,257,000. Krakauer stated, "We continue to maintain a strong balance sheet and generate substantial cash flow and EBITDAS. When compared with the same quarter last year, our EBITDAS grew by 36% to $15,680,000. We were able to reduce our net debt position by approximately $7 million to $96,854,000, since the close of the Byrne Medical acquisition on the first day of this quarter."

Cantel Medical Corp. (NYSE: CMN) is a leading provider of infection prevention and control products in the healthcare market. Our products include water purification equipment, sterilants, disinfectants and cleaners, specialized medical device reprocessing systems for endoscopy and renal dialysis, disposable infection control products primarily for dental and GI endoscopy markets, dialysate concentrates and other dialysis supplies, hollow fiber membrane filtration and separation products for medical and non-medical applications, and specialty packaging for the transport and temperature regulation of infectious and biological specimens.

The Company will hold a conference call to discuss the results for the first quarter ended October 31, 2011 on Thursday, December 8, 2011 at 11:00 AM Eastern time. To participate in the conference call, dial (877) 407-8033 approximately 5 to 10 minutes before the beginning of the call. If you are unable to participate, a digital replay of the call will be available from Thursday, December 8, 2011 at 2:00 PM through midnight on February 8, 2012 by dialing (877) 660-6853 and using pass code # 286 and conference ID # 384108.

The call will be simultaneously broadcast live over the Internet on at  A replay of the webcast will be available on Vcall for 90 days.

For further information, visit the Cantel website at

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve a number of risks and uncertainties, including, without limitation, the risks detailed in Cantel's filings and reports with the Securities and Exchange Commission. Such forward-looking statements are only predictions, and actual events or results may differ materially from those projected or anticipated.

 CANTEL MEDICAL CORP. CONDENSED CONSOLIDATED STATEMENTS OF INCOME(In thousands, except per share data)(unaudited) 






Three Months Ended 


October 31, 








 Net sales








 Cost of sales








 Gross profit
















9,631  General and administrative




9,118  Research and development




1,629Total operating expenses








 Income before interest and income taxes








 Interest expense 



241Interest income








 Income before income taxes








 Income taxes








 Net income 








 Earnings per common share - diluted 







 Dividends per common share 








 Weighted average shares - diluted 














October 31,


July 31, 







 Current assets




,324Property and equipment, net




34,459Intangible assets, net








134,770Other assets












 Liabilities and stockholders' equity 



 Current portion of long-term debt




-Other current liabilities




43,411Long-term debt




24,000Other long-term liabilities 




19,717Stockholders' equity





















 Reconciliation of Earnings Before Interest, Taxes, Depreciation, Amortization and Stock-Based Compensation Expense ("EBITDAS") 













 The reconciliation of EBITDAS with net income for the three months ended October 31, 2011 and 2010,

 respectively, is as follows (in thousands):
















Three Months Ended





October 31,
























 Net income














 Income taxes







 Interest expense 






 Interest income





















 Loss (gain) on disposal of fixed assets




























 Stock-based compensation expense










































 EBITDAS is a measure of the Company's performance that is not required by, or presented in accordance with,

 Generally Accepted Accounting Principles ("GAAP"). EBITDAS is a non-GAAP financial measure defined by the

 Company as income before interest, taxes, depreciation, amortization and stock-based compensation expense.

 The Company believes EBITDAS is an important valuation measurement for management and investors given

 the increasing effect that non-cash charges, such as stock-based compensation, amortization related to acquisitionsand depreciation of capital equipment, has on the Company's net income. In particular, acquisitions have historicallyresulted in significant increases in amortization of intangible assets that reduced the Company's net income.

 Additionally, the Company regards EBITDAS as a useful measure of operating performance and cash flow before

 the effect of interest expense and complements operating income, net income and other GAAP financial 

 performance measures. Generally, a non-GAAP financial measure is a numerical measure of a Company's 

 performance, financial position or cash flow that either excludes or includes amounts that are not normally excluded or included in the most directly comparable measure calculated and presented in accordance with GAAP. 

 This measure, however, should be considered in addition to, and not as a substitute or superior to, net income, 

 cash flows, or other measures of financial performance prepared in accordance with GAAP.




SOURCE Cantel Medical Corp.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Cantel Medical Corp. to Present at the Stephens Inc. Fall Investment Conference
2. Cantel Medical Board of Directors Authorizes Increase in Semiannual Dividend
3. Cantel Medical Corp. to Hold Conference Call to Discuss Fourth Quarter and Fiscal 2011 Results
4. Cantel Medicals Minntech Subsidiary Named Finalist for 2011 Tekne Awards
5. Cantel Medical Corp. to Present at the CL King 9th Annual Best Ideas Conference
6. Cantel Medical Acquires Byrne Medical, Inc., Substantially Increasing Its Presence in GI Endoscopy
7. Cantel Medical Reports 18% Increase in Net Income on 24% Increase in Sales
8. Cantel Medical Corp. to Present at the Needham & Company 10th Annual Healthcare Conference
9. Ann E. Berman To Join the Board of Directors of Cantel Medical Corp.
10. Cantel Medical Corp. to Present at The Sidoti & Company LLC Fifteenth Annual Emerging Growth Institutional Investor Forum
11. Cantel Medical Corp. to Hold Conference Call to Discuss Results for Its Second Quarter Ended January 31, 2011
Post Your Comments:
(Date:11/24/2015)... 2015 Teledyne DALSA , a Teledyne Technologies ... will introduce its CMOS X-Ray detector for mammography ... to December 3, at McCormick Place in Chicago ... and interventional imaging will be on display in the South ... advanced CMOS X-Ray detectors is the industry benchmark for high ...
(Date:11/24/2015)... , Nov. 24, 2015  Boston Scientific Corporation (NYSE: ... Oppenheimer 26th Annual Healthcare Conference on December 8, in ... Susie Lisa , vice president, Investor Relations, will participate ... beginning at approximately 8:35 a.m. ET. --> ... in a 30-minute question-and-answer session with the host analyst ...
(Date:11/24/2015)... November 24, 2015   ... dietician deliver s advice and insights on ... More than 50% of Dubai ... healthy according to the DHA   femMED launches comprehensive solutions ...    Dubai residents are not consuming enough to ...
Breaking Medicine Technology:
(Date:11/24/2015)... ... November 24, 2015 , ... Brillouin Energy ... Brillouin is the developer of renewable energy technologies capable of producing commercially useful ... announced today that its WET™ and HHT™ Boiler System reactor core modules were ...
(Date:11/24/2015)... , ... November 24, 2015 , ... ... the United States to support their local poison centers through donations on Tuesday, ... #GivingTuesday: calls it “a day that inspires people to collaborate in improving ...
(Date:11/24/2015)... ... , ... Aided by seed funding from the Ron Foley Foundation, researchers at ... into how to detect and treat pancreatic cancer (PC). , WCHN researchers will ... molecules (ncRNA), genetic material that is present in the blood of patients with PC. ...
(Date:11/24/2015)... ... ... Willey , has answered a new calling – to relieve snoring and sleep apnea for ... and sleep apnea through oral appliance therapy. He is one of a number ... of four in the Illinois area. , Dr. Willey’s location is at 11825 ...
(Date:11/24/2015)... ... , ... Autism Speaks, the world’s leading autism science and advocacy organization, will ... generosity of people around the world. On December 1, supporters can make an online ... share the personal stories behind those gifts. , Just as Black Friday and ...
Breaking Medicine News(10 mins):